A
Alfred W. Alberts
Researcher at Merck & Co.
Publications - 43
Citations - 4148
Alfred W. Alberts is an academic researcher from Merck & Co.. The author has contributed to research in topics: Lovastatin & HMG-CoA reductase. The author has an hindex of 25, co-authored 43 publications receiving 4046 citations.
Papers
More filters
Journal ArticleDOI
Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent.
Alfred W. Alberts,Julie S. Chen,G Kuron,V Hunt,Jesse W. Huff,Carl H. Hoffman,John W. Rothrock,Lopez Maria B,Henry Joshua,Elbert E. Harris,Arthur A. Patchett,R L Monaghan,S Currie,E Stapley,George Albers-Schonberg,Otto D. Hensens,J Hirshfield,Karst Hoogsteen,Jerrold M. Liesch,James P. Springer +19 more
TL;DR: It was shown that mevinolin was an orally active cholesterol-lowering agent in the dog and orally administered sodium mevinolinate was an active inhibitor of cholesterol synthesis in an acute assay.
Patent
Hypocholesteremic fermentation products and process of preparation
TL;DR: In this paper, the authors describe a class of highly active hypocholesteremic and hypolipemic medicaments, which are derived from a microorganism belonging to the genus Aspergillus.
Journal ArticleDOI
Discovery, biochemistry and biology of lovastatin
TL;DR: Lovastatin effectively diminishes endogenous cholesterol synthesis providing useful therapeutic properties for patients with hypercholesterolemia.
Journal ArticleDOI
Preclinical evaluation of lovastatin.
James S. MacDonald,Ronald J. Gerson,Douglas Kornbrust,Michelle W. Kloss,Srinivasa Prahalada,Peter H. Berry,Alfred W. Alberts,Delwin L. Bokelman +7 more
TL;DR: The presence of clear and high no-effect doses for these toxic effects along with the fact that most of the changes observed are clearly mechanism-based indicate that it is unlikely that similar changes will be observed at the therapeutic dosage levels in humans.
Journal ArticleDOI
Tissue selectivity of the cholesterol-lowering agents lovastatin, simvastatin and pravastatin in rats in vivo.
John I. Germershausen,Vincent M. Hunt,Richard G. Bostedor,Philip J. Bailey,John D. Karkas,Alfred W. Alberts +5 more
TL;DR: These studies demonstrate that the hydrophobic prodrugs, lovastatin and simvastatin show greater selectivity than thehydrophilic agent pravastatin towards the liver which is the target organ for inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase.